Non-alcoholic Steatohepatitis in Children

Clinics in Liver Disease

Volumn 11, Issue 1, 2007, Pages 155-172

  Roberts, Eve A ^a,b,c  

^a Hepatology and Nutrition and the Genetics   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADIPOCYTOKINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; METFORMIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; DIETARY INTAKE; DISEASE ASSOCIATION; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER BIOPSY; LIVER DISEASE; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; OBESITY; OXIDATIVE STRESS; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; MALE; RISK FACTORS;

EID: 34249715820     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.02.008     Document Type: Review

References (152)

1. Lobstein T., Baur L., and Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev 5 Suppl 1 (2004) 4-104
2. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 13 (2006) 1549-1555
3. Moran J.R., Ghishan F.K., Halter S.A., et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 78 6 (1983) 374-377
4. Kinugasa A., Tsunamoto K., Furukawa N., et al. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gatroenterol Nutr 3 3 (1984) 408-414
5. Baldridge A.D., Perez-Atayde A.R., Graeme-Cooke F., et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 127 5 (1995) 700-704
6. Rashid M., and Roberts E.A. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 30 1 (2000) 48-53
7. Schwimmer J.B., Deutsch R., Rauch J.B., et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 143 4 (2003) 500-505
8. Squires Jr. R.H., and Lopez M.J. Steatohepatitis (SH) is a serious condition in Hispanic children. [abstract]. Hepatology 32 4 (2000) 418A
9. Chan D.F., Li A.M., Chu W.C., et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 28 10 (2004) 1257-1263
10. Xanthakos S., Miles L., Bucuvalas J., et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 4 2 (2006) 226-232
11. Schwimmer J.B., McGreal N., Deutsch R., et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 115 5 (2005) e561-e565
12. Weston S.R., Leyden W., Murphy R., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41 2 (2005) 372-379
13. Louthan M.V., Theriot J.A., Zimmerman E., et al. Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterol Nutr 41 4 (2005) 426-429
14. Talvensaari K.K., Lanning M., Tapanainen P., et al. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 81 8 (1996) 3051-3055
15. Jarfelt M., Lannering B., Bosaeus I., et al. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol 153 1 (2005) 81-89
16. Kourti M., Tragiannidis A., Makedou A., et al. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol 27 9 (2005) 499-501
17. Ness K.K., Oakes J.M., Punyko J.A., et al. Prevalence of the metabolic syndrome in relation to self-reported cancer history. Ann Epidemiol 15 3 (2005) 202-206
18. Molleston J.P., White F., Teckman J., et al. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 97 9 (2002) 2460-2462
19. Adams L.A., Feldstein A., Lindor K.D., et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39 4 (2004) 909-914
20. Basenau D., Stehphani U., and Fischer G. [Development of complete liver cirrhosis in hyperphagia-induced fatty liver]. Klin Pädiatr 206 (1994) 62-64 [German]
21. Altuntas B., Ozcakar B., Bideci A., et al. Cirrhotic outcome in patients with craniopharyngioma. J Pediatr Endocrinol Metab 15 7 (2002) 1057-1058
22. Brunt E.M., Neuschwander-Tetri B.A., Oliver D., et al. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 35 9 (2004) 1070-1082
23. Evans H.M., Shaikh M.G., McKiernan P.J., et al. Acute fatty liver disease after suprasellar tumor resection. J Pediatr Gastroenterol Nutr 39 3 (2004) 288-291
24. Nakajima K., Hashimoto E., Kaneda H., et al. Pediatric nonalcoholic steatohepatitis associated with hypopituitarism. J Gastroenterol 40 3 (2005) 312-315
25. Srinivasan S., Ogle G.D., Garnett S.P., et al. Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab 89 1 (2004) 81-86
26. Yigit S., Estrada E., Bucci K., et al. Diabetic ketoacidosis secondary to growth hormone treatment in a boy with Prader-Willi syndrome and steatohepatitis. J Pediatr Endocrinol Metab 17 3 (2004) 361-364
27. Willner I.R., Waters B., Patil S.R., et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96 10 (2001) 2957-2961
28. Michaud J.L., Heon E., Guilbert F., et al. Natural history of Alstrom syndrome in early childhood: onset with dilated cardiomyopathy. J Pediatr 128 2 (1996) 225-229
29. Awazu M., Tanaka T., Sato S., et al. Hepatic dysfunction in two sibs with Alstrom syndrome: case report and review of the literature. Am J Med Genet 69 1 (1997) 13-16
30. Quiros-Tejeira R.E., Vargas J., and Ament M.E. Early-onset liver disease complicated with acute liver failure in Alstrom syndrome. Am J Med Genet 101 1 (2001) 9-11
31. Satman I., Yilmaz M.T., Gursoy N., et al. Evaluation of insulin resistant diabetes mellitus in Alstrom syndrome: a long-term prospective follow-up of three siblings. Diabetes Res Clin Pract 56 3 (2002) 189-196
32. Marshall J.D., Bronson R.T., Collin G.B., et al. New Alstrom syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med 165 6 (2005) 675-683
33. Lewy V.D., Danadian K., Witchel S.F., et al. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 138 1 (2001) 38-44
34. Setji T.L., Holland N.D., Sanders L.L., et al. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 5 (2006) 1741-1747
35. Schwimmer J.B., Khorram O., Chiu V., et al. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 83 2 (2005) 494-497
36. Brown A.J., Tendler D.A., McMurray R.G., et al. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract 11 5 (2005) 319-324
37. Karlberg N., Jalanko H., Kallijarvi J., et al. Insulin resistance syndrome in subjects with mutated RING finger protein TRIM37. Diabetes 54 12 (2005) 3577-3581
38. Tan T.Y., Bankier A., Slater H.R., et al. A patient with monosomy 1p36, atypical features and phenotypic similarities with Cantu syndrome. Am J Med Genet A 139 3 (2005) 216-220
39. Srinivasan R., Hadzic N., Fischer J., et al. Steatohepatitis and unsuspected micronodular cirrhosis in Dorfman-Chanarin syndrome with documented ABHD5 mutation. J Pediatr 144 5 (2004) 662-665
40. Magre J., Delepine M., Khallouf E., et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 28 4 (2001) 365-370
41. Shackleton S., Lloyd D.J., Jackson S.N., et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24 2 (2000) 153-156
42. Lloyd D.J., Trembath R.C., and Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet 11 (2002) 769-777
43. Agarwal A.K., and Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87 (2002) 408-411
44. Ludtke A., Genschel J., Brabant G., et al. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am J Gastroenterol 100 10 (2005) 2218-2224
45. Simha V., and Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 17 2 (2006) 162-169
46. Reitman M.L., Arioglu E., Gavrilova O., et al. Lipoatrophy revisited. Trends Endocrinol Metab 11 10 (2000) 410-416
47. Powell E.E., Searle J., and Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 97 4 (1989) 1022-1024
48. Cauble M.S., Gilroy R., Sorrell M.F., et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 71 7 (2001) 892-895
49. Pietilainen K.H., Rissanen A., Kaprio J., et al. Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol Endocrinol Metab 288 4 (2005) E768-E774
50. Westerbacka J., Lammi K., Hakkinen A.M., et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 90 5 (2005) 2804-2809
51. Birkner E., Kasperczyk S., Kasperczyk A., et al. Metabolic and antioxidative changes in liver steatosis induced by high-fat, low-carbohydrate diet in rabbits. J Physiol Pharmacol 56 Suppl 6 (2005) 45-58
52. Wolever T.M., Jenkins D.J., Jenkins A.L., et al. The glycemic index: methodology and clinical implications. Am J Clin Nutr 54 5 (1991) 846-854
53. Ma Y., Olendzki B., Chiriboga D., et al. Association between dietary carbohydrates and body weight. Am J Epidemiol 161 4 (2005) 359-367
54. 2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29 4 (2006) 853-857
55. Bugianesi E., Pagotto U., Manini R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90 6 (2005) 3498-3504
56. Pagano C., Soardo G., Esposito W., et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152 1 (2005) 113-118
57. Louthan M.V., Barve S., McClain C.J., et al. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 147 6 (2005) 835-838
58. Gil-Campos M., Canete R.R., and Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 23 5 (2004) 963-974
59. Wanless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 5 (1990) 1106-1110
60. de Almeida I.T., Cortez-Pinto H., Figaldo G., et al. Plasma total and free fatty acids compsition in human non-alcoholic steatohepatitis. Clin Nutr 21 3 (2002) 219-223
61. Day C.P. Pathogenesis of steaohepatitis. Best Pract Res Clin Gastroenterol 16 5 (2002) 663-678
62. Boden G., She P., Mozzoli M., et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes 54 12 (2005) 3458-3465
63. Malhi H., Bronk S.F., Werneburg N.W., et al. Free fatty acids induce JNK dependent hepatocyte lipoapoptosis. J Biol Chem 281 17 (2006) 12093-12101
64. Schattenberg J.M., Singh R., Wang Y., et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43 1 (2006) 163-172
65. Ueki K., Kadowaki T., and Kahn C.R. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 33 2 (2005) 185-192
66. Schattenberg J.M., Wang Y., Singh R., et al. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 280 11 (2005) 9887-9894
67. Orellana M., Rodrigo R., Varela N., et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 34 1 (2006) 57-63
68. Molnar D., Decsi T., and Koletzko B. Reduced antioxidant status in obese children with multimetabolic syndrome. Int J Obes Relat Metab Disord 28 10 (2004) 1197-1202
69. Mager D.R., Rogenstein C.D., and Roberts E.A. A high glycemic index diet: a contribution to the pathogenesis of childhood NAFLD?. [abstract]. FASEB J 20 5 (2006) A857
70. Brunt E.M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21 1 (2001) 3-16
71. Abrams G.A., Kunde S.S., Lazenby A.J., et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 40 2 (2004) 475-483
72. Struben V.M., Hespenheide E.E., and Caldwell S.H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108 1 (2000) 9-13
73. Caldwell S.H., and Crespo D.M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40 4 (2004) 578-584
74. Schwimmer J.B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42 3 (2005) 641-649
75. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 5 (2001) 1183-1192
76. Caldwell S.H., Chang C.Y., Nakamoto R.K., et al. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8 3 (2004) 595-617
77. Le T.H., Caldwell S.H., Redick J.A., et al. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 39 5 (2004) 1423-1429
78. Sobaniec-Lotowska M.E., and Lebensztejn D.M. Ultrastructure of hepatocyte mitochondria in nonalcoholic steatohepatitis in pediatric patients: usefulness of electron microscopy in the diagnosis of the disease. Am J Gastroenterol 98 7 (2003) 1664-1665
79. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 6 (1999) 1413-1419
80. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 1 (2005) 113-121
81. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 1 (2005) 132-138
82. Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 4 (2004) 820-826
83. Fishbein M., and Cox S. Non-alcoholic fatty liver disease in a toddler. Clin Pediatr (Phila) 43 5 (2004) 483-485
84. Dietz W.H. Overweight in childhood and adolescence. N Engl J Med 350 9 (2004) 855-857
85. Cole T.J., Bellizzi M.C., Flegal K.M., et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320 7244 (2000) 1240-1243
86. Cole T.J., Faith M.S., Pietrobelli A., et al. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile?. Eur J Clin Nutr 59 3 (2005) 419-425
87. Mei Z., Grummer-Strawn L.M., Pietrobelli A., et al. Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. Am J Clin Nutr 75 6 (2002) 978-985
88. Fishbein M.H., Mogren C., Gleason T., et al. Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 42 1 (2006) 83-88
89. Taylor R.W., Jones I.E., Williams S.M., et al. Evaluation of waist circumference, waist-to-hip ratio, and the conicity index as screening tools for high trunk fat mass, as measured by dual-energy X-ray absorptiometry, in children aged 3-19 y. Am J Clin Nutr 72 2 (2000) 490-495
90. Fernandez J.R., Redden D.T., Pietrobelli A., et al. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 145 4 (2004) 439-444
91. McCarthy H.D., Jarrett K.V., Emmett P.M., et al. Trends in waist circumferences in young British children: a comparative study. Int J Obes Relat Metab Disord 29 2 (2005) 157-162
92. Janssen I., Katzmarzyk P.T., Srinivasan S.R., et al. Combined influence of body mass index and waist circumference on coronary artery disease risk factors among children and adolescents. Pediatrics 115 6 (2005) 1623-1630
93. Fredriks A.M., van Buuren S., Fekkes M., et al. Are age references for waist circumference, hip circumference and waist-hip ratio in Dutch children useful in clinical practice?. Eur J Pediatr 164 4 (2005) 216-222
94. Pecoraro P., Guida B., Caroli M., et al. Body mass index and skinfold thickness versus bioimpedance analysis: fat mass prediction in children. Acta Diabetol 40 Suppl 1 (2003) S278-S281
95. Gelbrich G., Reich A., Muller G., et al. Knowing more by fewer measurements: about the (In)ability of bioelectric impedance to enhance obesity research in children. J Pediatr Endocrinol Metab 18 3 (2005) 265-273
96. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 6 (2005) 1313-1321
97. Canbay A., Bechmann L.P., Best J., et al. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z Gastroenterol 44 3 (2006) 245-248
98. Tan H., Orbak Z., Kantarci M., et al. Valproate-induced insulin resistance in prepubertal girls with epilepsy. J Pediatr Endocrinol Metab 18 10 (2005) 985-989
99. Ramesh S., and Sanyal A.J. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 24 4 (2004) 399-413
100. Camma C., Bruno S., Di Marco V., et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43 1 (2006) 64-71
101. Guidi M., Muratori P., Granito A., et al. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther 22 10 (2005) 943-949
102. Yaginuma R., Ikejima K., Okumura K., et al. Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. Hepatol Res 35 1 (2006) 19-25
103. Walsh M.J., Jonsson J.R., Richardson M.M., et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55 4 (2006) 529-535
104. Perumalswami P., Kleiner D.E., Lutchman G., et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 43 4 (2006) 780-787
105. Riley M.R., Bass N.M., Rosenthal P., et al. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr 147 6 (2005) 839-842
106. Fishbein M., Mogren J., Mogren C., et al. Undetected hepatomegaly in obese children by primary care physicians: a pitfall in the diagnosis of pediatric nonalcoholic Fatty liver disease. Clin Pediatr (Phila) 44 2 (2005) 135-141
107. Phipps S.A., Burton P.S., Osberg L.S., et al. Poverty and the extent of child obesity in Canada, Norway and the United States. Obes Rev 7 1 (2006) 5-12
108. Lumeng J.C., Appugliese D., Cabral H.J., et al. Neighborhood safety and overweight status in children. Arch Pediatr Adolesc Med 160 1 (2006) 25-31
109. Vajro P., Fontanella A., Perna C., et al. Persistent hypertransaminasemia resolving after weight reduction in obese children. J Pediatr 125 2 (1994) 239-241
110. Vajro P., Franzese A., Valerio G., et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 136 6 (2000) 739-743
111. Jenkins D.J., Wolever T.M., Kalmusky J., et al. Low glycemic index carbohydrate foods in the management of hyperlipidemia. Am J Clin Nutr 42 4 (1985) 604-617
112. Ludwig D.S. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 287 18 (2002) 2414-2423
113. Spieth L.E., Harnish J.D., Lenders C.M., et al. A low-glycemic index diet in the treatment of pediatric obesity. Arch Pediatr Adolesc Med 154 9 (2000) 947-951
114. Ebbeling C.B., Leidig M.M., Sinclair K.B., et al. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 157 8 (2003) 773-779
115. Ebbeling C.B., Leidig M.M., Sinclair K.B., et al. Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr 81 5 (2005) 976-982
116. Lahaye S.A., Hollett P.M., Vyselaar J.R., et al. Comparison between a low glycemic load diet and a Canada food guide diet in cardiac rehabilitation patients in Ontario. Can J Cardiol 21 6 (2005) 489-494
117. Qi L., Rimm E., Liu S., et al. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 28 5 (2005) 1022-1028
118. Pischon T., Girman C.J., Rifai N., et al. Association between dietary factors and plasma adiponectin concentrations in men. Am J Clin Nutr 81 4 (2005) 780-786
119. Zametkin A.J., Zoon C.K., Klein H.W., et al. Psychiatric aspects of child and adolescent obesity: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 43 2 (2004) 134-150
120. Golan M., Kaufman V., and Shahar D.R. Childhood obesity treatment: targeting parents exclusively v. parents and children. Br J Nutr 95 5 (2006) 1008-1015
121. Vandewater E.A., Shim M.S., and Caplovitz A.G. Linking obesity and activity level with children's television and video game use. J Adolesc 27 1 (2004) 71-85
122. Jago R., Baranowski T., Baranowski J.C., et al. BMI from 3-6 y of age is predicted by TV viewing and physical activity, not diet. Int J Obes Relat Metab Disord 29 6 (2005) 557-564
123. Vermorel M., Lazzer S., Bitar A., et al. Contributing factors and variability of energy expenditure in non-obese, obese, and post-obese adolescents. Reprod Nutr Dev 45 2 (2005) 129-142
124. Page A., Cooper A.R., Stamatakis E., et al. Physical activity patterns in nonobese and obese children assessed using minute-by-minute accelerometry. Int J Obes Relat Metab Disord (2005)
125. Salmon J., Ball K., Crawford D., et al. Reducing sedentary behaviour and increasing physical activity among 10-year-old children: overview and process evaluation of the 'Switch-Play' intervention. Health Promot Int 20 1 (2005) 7-17
126. Vandewater E.A., and Huang X. Parental weight status as a moderator of the relationship between television viewing and childhood overweight. Arch Pediatr Adolesc Med 160 4 (2006) 425-431
127. Nassis G.P., Papantakou K., Skenderi K., et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metabolism 54 11 (2005) 1472-1479
128. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136 6 (2000) 734-738
129. Vajro P., Mandato C., Franzese A., et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 38 1 (2004) 48-55
130. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 5 (2005) 1082-1090
131. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98 11 (2003) 2485-2490
132. Sanyal A.J., Mofrad P.S., Contos M.J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 12 (2004) 1107-1115
133. Kugelmas M., Hill D.B., Vivian B., et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38 2 (2003) 413-419
134. Marchesini G., Brizi M., Bianchi G., et al. Metformin in non-alcoholic steatohepatitis. Lancet 358 9285 (2001) 893-894
135. Nair S., Diehl A.M., Wiseman M., et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20 1 (2004) 23-28
136. Schwimmer J.B., Middleton M.S., Deutsch R., et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 21 7 (2005) 871-879
137. Kay J.P., Alemzadeh R., Langley G., et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50 12 (2001) 1457-1461
138. Freemark M., and Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107 4 (2001) E55
139. Jones K.L., Arslanian S., Peterokova V.A., et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 25 1 (2002) 89-94
140. Glueck C.J., Wang P., Fontaine R., et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 29 3 (2001) 160-169
141. Arslanian S.A., Lewy V., Danadian K., et al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87 4 (2002) 1555-1559
142. Chan N.N., Feher M.D., and Bridges N.A. Metformin therapy for diabetes in Prader-Willi syndrome. J R Soc Med 91 11 (1998) 598
143. Halford J.C. Pharmacotherapy for obesity. Appetite 46 1 (2006) 6-10
144. Berkowitz R.I., Wadden T.A., Tershakovec A.M., et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 289 14 (2003) 1805-1812
145. Reisler G., Tauber T., Afriat R., et al. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 8 1 (2006) 30-32
146. Chanoine J.P., Hampl S., Jensen C., et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293 23 (2005) 2873-2883
147. Scheen A.J. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs 63 10 (2003) 933-951
148. Ioannides-Demos L.L., Proietto J., Tonkin A.M., et al. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 29 4 (2006) 277-302
149. Greenway F.L., and Caruso M.K. Safety of obesity drugs. Expert Opin Drug Saf 4 6 (2005) 1083-1095
150. Oral E.A., Simha V., Ruiz E., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346 8 (2002) 570-578
151. Javor E.D., Ghany M.G., Cochran E.K., et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41 4 (2005) 753-760
152. Javor E.D., Cochran E.K., Musso C., et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54 7 (2005) 1994-2002